NR3C1 and posterior cortical atrophy: Such studies are likely to identify the GR–LEDGF/p75 transcriptional network as a novel driver of therapy cross-resistance and an attractive target for adjuvant therapies using SGRMs and LEDGF/p75 inhibitors that are designed to increase taxane response in PCa patients.